Results 91 to 100 of about 3,967,313 (340)

Efficacy of Inebilizumab in N‐MOmentum Trial Participants With or Without Prior Immunosuppressants

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This post hoc analysis examined the impact of prior immunosuppressants on the long‐term efficacy and safety of inebilizumab, a cluster of differentiation 19+ B‐cell–depleting monoclonal antibody, in participants with aquaporin‐4–seropositive neuromyelitis optica spectrum disorder from the N‐MOmentum trial (NTC02200770).
Bruce A. C. Cree, Beatrice Suero, Sarah Walsh, Romain Marignier, John W. Lindsey, Ho Jin Kim, Dewei She, Daniel Cimbora, Dustin Cavida, Friedemann Paul   +9 more
wiley   +1 more source

Beauty and Health: Anthropological Perspectives [PDF]

, 2008
This essay, written as a 'teaser' for an up-coming symposium, reflects on how human beauty can be understood from an anthropological and medical anthropological perspective.
Edmonds, Alexander
core  

Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity. [PDF]

, 2013
A crisis continues to brew within the pharmaceutical research and development (R&D) enterprise: productivity continues declining as costs rise, despite ongoing, often dramatic scientific and technical advances. To reverse this trend, we offer various
Hunt, C. Anthony, Hunt, CA, Kennedy, RC, Kim, SHJ, Ropella, GEP   +4 more
core   +2 more sources

Safety of Prescription Nonsteroidal Anti‐inflammatory Drugs in Adults With Inflammatory Bowel Disease: Data From a Large Administrative Claims Cohort

Arthritis Care &Research, EarlyView.
Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer, Rui Xiao, Meenakshi Bewtra, Michael D. George, Pamela F. Weiss   +4 more
wiley   +1 more source

High-quality patents for emerging science and technology through external actors: community scientific experts and knowledge societies [PDF]

, 2010
This article explores one type of administrative mechanism to achieve high-quality patents: Article 115 of the European Patent Convention, which permits the inclusion of third parties to provide input to the prior art search and to communicate relevant ...
Groenendijk, Nico, Kica, Evisa, Rodriguez, Victor   +2 more
core   +1 more source

The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]

, 2014
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER, Brooks, Brown, Buse, Chaudhuri, Clarke, Cooper Ramo, Drezner, Elbe, Fleury, Gold, Knight, Levy, Meyer, Petryna, Ramamurti, Roemer-Mahler, Schoofs, Wells, Whyte, Williams, Williamson, Youde, Zimmerman   +23 more
core   +1 more source

Clinical, histological, and serological predictors of renal function loss in lupus nephritis.

Arthritis Care &Research, Accepted Article.
Objective Kidney survival is the ultimate goal in lupus nephritis (LN) management, but long‐term predictors remain inadequately studied, requiring long‐term follow‐up. This study aimed to identify baseline and early longitudinal predictors of kidney survival in the Accelerating Medicines Partnership LN longitudinal cohort.
Shangzhu Zhang, Laurence Magder, Daniel Goldman, Judith A. James, Joel M Guthridge, Carla Guthridge, Peter Izmirly, Jill P Buyon, H.Michael Belmont, Richard A. Furie, Noa Schwartz, Chaim Putterman, Jennifer L. Barnas, Jennifer H. Anolik, Sarah French, Maria Dall'era, Avi Z. Rosenberg, Jeffrey Hodgin, Dawit S. Demeke, the Accelerating Medicines Partnership RA/SLE Network, Michelle Petri, Andrea Fava   +21 more
wiley   +1 more source

The human right to medicines [PDF]

, 2008
This article considers the component of the right to the highest standard of health that relates to medicines, including essential medicines. Using the right-to-health analytical framework that has been developed in recent years, the first section ...
Hunt, PH, Khosla, R
core  

Supplementing food for health: Practices amongst French adults aged 60 to 75 years [PDF]

, 2018
The use of food supplements continues to grow in France, even though it is being discouraged by the main health and medical authorities. The ambiguous definitions surrounding these products make it difficult to measure their consumption.
A Baubérot, A Drouard, A Grisoni, A Reckwitz, A Rochedy, A Stanziani, A Warde, A Warde, A Warde, A-C Bégot, ANSES, ANSES, ANSES, AP Ouedraogo, C Lamine, C Lawrence, C Peter, C Pouchieu, CA Bisogni, CE Mykytyn, CM Devine, CREDOC, D Léger, D Servan-Schreiber, DGCCRF, E-H Guitard, F Laplantine, F Régnier, G Enders, J Clapp, J Coveney, J Seignalet, J-F Barthe, J-P Olivier de Sardan, J-P Poulain, JL Austin, L Auvray, L Berlivet, L Cynober, M Plessz, M Plessz, M Touvier, M Weber, O Lepiller, O Lepiller, P Cardon, P Cardon, P Le-Bras, RH Binstock, S Derbré, S Fainzang, S Gojard, S Lahlou, S Schraub, T Depecker, T Fournier, T Pilorin, TR Schatzki, V Caradec, WJ Belasco, Y Besson   +60 more
core   +2 more sources

The duty to be morally enhanced

Topoi, 2017
We have a duty to try to develop and apply safe and cost-effective means to increase the probability that we shall do what we morally ought to do.
I. Persson, J. Savulescu
semanticscholar   +1 more source